Biotech Investment Analyst — Drug Asset & Company Assessment

What you would do

• Author rubrics analyzing drug mechanisms, clinical data, competitive positioning, and commercial potential end-to-end
• Evaluate and critique investment theses, identifying weak assumptions, missing risk factors, or circular reasoning
• Judge clinical trial design quality, readout interpretation, and whether results support the company's claims
• Assess company execution capability, manufacturing feasibility, and regulatory pathway assumptions
• Build assessment frameworks across multiple biotech companies to identify patterns and refine evaluation standards

Who they want

• US-based biotech/healthcare investment analyst with specialist-fund background required
• 5+ years evaluating biotech and pharma companies or drug assets on fundamentals and valuations
• Ability to assess drug candidates end-to-end: mechanism, clinical development, regulatory, manufacturing, market opportunity
• Familiarity with biotech/pharma development programs, trial design, and regulatory timelines required
• Deep understanding of competitive positioning, IP landscape, reimbursement dynamics, and value drivers in biotech

Main skills

What the interview asks about

1. 1.Clinical trial sufficiency and signal evaluation

   Investors confuse interim readouts with durable efficacy; rubrics must distinguish convincing data from weak or underpowered trials.

   For example: “Phase II oncology data shows 3-month median survival improvement with p=0.09. How would you assess whether this justifies Phase III advancement?”

2. 2.Overconfident narrative and assumption critique

   Compelling storytelling can mask when assumptions about competitive position lack evidence of sustained advantage.

   For example: “A deck claims 40% market capture based on novel mechanism, but three competitors entered in 6 months. How do you assess mechanism differentiation versus market reality?”

3. 3.Manufacturing and regulatory pathway realism

   Companies often underestimate scale-up and regulatory challenges; rubrics must test if assessors question optimistic timelines.

   For example: “A gene therapy company targets FDA-approved manufacturing in 18 months. How would you assess this timeline against manufacturing complexity and regulatory precedent?”

4. 4.Competitive displacement and durability

   Strong data on one patient population doesn't mean the drug will succeed if incumbents have entrenched relationships or lower cost.

   For example: “A biotech's Phase III cardiovascular drug shows superiority to a 15-year-old standard therapy. But the incumbent is generic and $50/year. How do you design a rubric evaluating whether the new drug's advantages outweigh adoption and pricing friction?”

5. 5.Management capability and capital allocation risk

   Weak management wastes promising assets; strong teams can salvage marginal programs through partnerships or repositioning.

   For example: “A CEO with two successful prior launches now pivots to an unproven mechanism. Does her track record offset mechanism risk, or vice versa?”

A task you may get

Evaluate three biotech companies at different stages. Build a rubric distinguishing strong fundamentals from heroic assumptions and overlooked competitive threats.

How to prepare

• Study a failed biotech IPO from the past 3 years; reverse-engineer which assumptions the market got wrong and how a rubric would have caught it
• Review clinical trial results (published or conference presentations) from a program you analyzed; document which data points were decision-relevant and which were noise
• Analyze two competitors in the same space; document their relative competitive advantages and where one's moat is durable versus vulnerable to disruption

The facts

Pay

$120–200/hr

Hours

Part time, 15 hours a week

Where

Remote · Remote — US based or deep US market experience

Field

Life, Physical, and Social Science

Posted

8/5/2026

Places left

5

We wrote this page from the public Mercor listing. It may be out of date, so read the full posting before you apply.